Welcome to RealPatient ALL
RealPatient is your self-guided tour through published sources of CAR‑T real-world evidence and clinical trial data.
Select patient profiles of interest and view relevant real-world outcomes in specific populations in addition to clinical data. Latest data sources are updated regularly.
Disclaimer: This resource is an educational application only for worldwide healthcare professionals. It includes publicly available CAR‑T real-world evidence from large international and national registries and pivotal clinical trials.
© 2023 - www.cellcompass.com
Use of website governed by the Terms of Service and Privacy Policy. Copyright © 2023 Novartis AG. All rights reserved.
Who is your CAR‑T patient?
Tisagenlecleucel is a CD19-directed genetically modified autologous T-cell immunotherapy indicated for the treatment of pediatric and young adult patients up to and including 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.
09/23 159972-1